Free Essay

Gsk Patents

In: Business and Management

Submitted By txwdbat
Words 383
Pages 2
Through analyzing the competitors of GSK, including Merck, AstraZeneca, Pfizer, Eli Lilly, Roche, Sanofi. We found that AstraZeneca and Pfizer are the biggest threats for GSK in many areas such as Respiratory, CNS disorders etc. Therefore, we compared GSK with these two companies to evaluate the competitive advantages of GSK.

USD $ in millions, translated from GBP £ | | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | | Land and buildings | 10,538 | 9,654 | 9,263 | 9,457 | 8,506 | | Plant, equipment and vehicles | 16,105 | 15,454 | 15,550 | 16,361 | 15,020 | | Assets in construction | 3,056 | 3,148 | 3,343 | 3,523 | 3,330 | | Property, plant and equipment, cost | 29,699 | 28,255 | 28,156 | 29,340 | 26,857 | | Accumulated depreciation | (15,427) | (14,663) | (14,234) | (14,184) | (12,708) | | Property, plant and equipment, net book value | 14,272 | 13,592 | 13,922 | 15,156 | 14,149 |

Patents 2013年数据 Assignee | No. of patent families | No. of patent families as 1st assignee | GLAXOSMITHKLINE (UK) | 37 | 32 | SANOFI-AVENTIS (FR) | 21 | 20 | US GOVERNMENT (US) | 21 | 12 | WYETH CORP (US) | 20 | 15 | NOVARTIS CORP (CH) | 19 | 13 | MERCK AND CO INC (US) | 15 | 14 | SEPPIC SA (FR) | 12 | 9 | BISEIBUTSU KAGAKU KENKYUSHO (JP) | 11 | 10 | KITASATO INST (JP) | 8 | 6 | PFIZER CORP (US) | 8 | 6 | AQUILA BIOPHARM INC (US) | 8 | 4 | UNIVERSITY OF CALIFORNIA (US) | 7 | 5 | EISAI CO LTD (JP) | 7 | 6 | STATENS SERUMINSTITUT (DK) | 6 | 6 | ANVAR (FR) | 6 | 6 | CHEMO-SERO THERAPEUTICS RESEARCH INSTITUTE (JP) | 6 | 2 | CSL LTD (AU) | 6 | 5 | DUKE UNIVERSITY (US) | 6 | 6 | AKZO NOBEL NV (NL) | 6 | 6 | GENEXINE INC (KR) | 5 | 3 | UNIVERSITY ZHEJIANG (CN) | 5 | 5 | IST SUPERIORE SANITA (IT) | 5 | 5 | PF MEDICAMENT (FR) | 5 | 3 | UNIVERSITY FUDAN (CN) | 5 | 5 | UNIVERSITY NEW YORK (US) | 5 | 5 | ANTIGENICS INC (US) | 8 | | CHEMO SERO THERAPEUT RES INST (JP) | 6 | | PF MEDICAMENT (FR) | 5 | | Totals | 279 | 209 |

R&D
In 2012, GSK disclosed that our IRR on R&D spend was approximately 12%

MANAGEMENT SKILL * Design of new seating plan---50 million dollars each product line you don’t need to schedule a meeting to share ideas—which could take a month. You just lean over and start talking. And these informal interactions spark creative energy.” *

Similar Documents

Premium Essay

Gsk, a Merger Too Far?

...Strategic Management Case study C: GSK, a merger too far? Answer 1: 1. By using Five Force Framework, assess the threat of rivalry and threat of entry in the pharmaceutical industry: Threats of rivalry. When we talk about threats of rivalry we should mention not only the rivalry at the industry but also at the product market level. Industry level The pharmaceutical industry has become increasingly concentrated during last 20 years. Guided by absence of proper R&D facilities, gradual expiry of patents and other reasons, there has been a number of mergers and acquisitions in the industry within last 20 years. This trend is currently shaping the internal rivalry among companies. The major reasons for that are opportunistic financial operations and the creation of synergy. It is worth mentioning that some companies would prefer to merge than to experience hostile takeover. Product market level: The two-tier structure has to be taken into account: patented original brands vs. generics. Original compete mostly on non-price benefits, especially as long as they are patent protected, whereas generic drug are generally driven by price competition. The threats of entry. The threats of entry into the pharmaceutical industry are extremely high. Still, it is considered to be very attractive for the new comers. As an evidence for that, 21 pharmaceuticals are featured in the Fortune 500 companies in return on sales. The pharmaceutical industry has big barriers to prevent new comers......

Words: 1222 - Pages: 5

Premium Essay

Mba Essay

...A “Calibrated Approach”: Pharmaceutical FDI and the Evolution of Indian Patent Law Web version: August 2007 Authors: Katherine Connor Linton and Nicholas Corrado1 Abstract India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India’s movement towards compliance with the W TO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian “calibrated approach” to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen. 1 Katherine Connor Linton (katherine.linton@usitc.gov) is the International Trade Analyst for Intellectual Property and Nicholas Corrado was a law student intern in the Office of Industries of the U.S. International Trade Commission (USITC). The views expressed are those of Ms. Linton......

Words: 6873 - Pages: 28

Premium Essay

Gsk a Merger Too Far

...GSK, a merger too far? 1- Analyse these two forces : * Threat of entry : Very important * Very high expenses on advertising Direct to Consumer (DTC) * In this industry some specific skills to manufacture drugs are required, because they need to pass severe clinical trials before being commercialized. * It can take a very long time to become profitable and to compensate the speeding in R&D. * The whole industry has a bad reputation because of former issues so it is difficult to have a positive image. * Also, you need numerous sales representatives to have a real impact on the market and to get a global commercial reach. * Threat of rivalry : important * Even niches areas in this industry are more and more crowded. * The top 10 pharmaceutical firms stand for 50% of the global sales. * There is he generic competition from which branded drugs producers are suffering. Indeed when the lifetime of a patent is over , generic companies rush to the market and offer drugs with the same active components but in a very low cost. There is also a real competition between generic companies. * Medium-sized pharmas have to consider M&A as a survival strategy. 2- Which factors explain the wave of mergers and acquisitions in the pharmaceutical industry? The pharmaceutical industry is a really special one, on the contrary of the most part of industries there is very few new products coming to market. Indeed, a lot of money and a......

Words: 951 - Pages: 4

Premium Essay

Case Study Gsk

...GSK Gary Benillouche Sylvain Descazeaud Stéphane Nooroya Yousra Zaghdoud Bernichi Case C : GSK 1 - Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. |Political |Economic |Social | |Governments are looking for reduce healthcare|The current economic crisis. |Population is getting older. | |costs. | | | | |Cost structure at ethical pharmaceutical |Increasing awareness of people thanks to the | |There is no convergence of healthcare system |companies: manufacturing of goods (25%), R&D |Internet : new demand and changing | |: people don't get always reimbursed their |(12 to 21%), administration (10%), sales and |expectation. | |health costs around the world. |marketing (25%). | | | | |Rise in the number of obese people. | | |New kind of competition with generics drugs. | ...

Words: 1254 - Pages: 6

Premium Essay

Gsk Merger

...Abstract Mergers and acquisitions often referred to as M&A is also a tool for expanding ones business or get around different laws or regulations such as tax laws or monopoly regulations (Ross et al., 2002). Merger and acquisition (M &A) has been the most debatable issue in the field of management and finance. There are arguments for and against corporate restructuring and mergers. Lambrecht (2005) argued that although M&A activities occur in waves but M&A activities are as a result of the economic environment. This paper examines whether such corporate marriages long lasting and productive in term of value? We have analyzed the pre and post merger performance of Glaxo Smith Kline by applying the net present value approach of valuation. From the very beginning, Barron's (2000) called this merger as ‘‘a marriage of convenience-with lots of tough issues to be worked out … SmithKline is wedding itself to a slow-moving company with a lackluster pipeline of new drugs coming to market’’. We found that mega pharmaceutical merger hasn’t delivered value. The stock prices underperform both in absolute and relative terms against the index. The merger has resulted into a substantial R&D reduction and downsizing instead of a potential employment haven. Background ‘‘All Marriages are Happy. It’s the life afterwards that creates troubles’’ (Anonymous) A merger or acquisition happens when two or more companies join together, often to share costs, increase efficiency or......

Words: 1304 - Pages: 6

Free Essay

Glaxosmithkline

...GlaxoSmithKline (GSK), is confronted with a question of ethics. Do they go the humanitarian route and provide drugs for AIDS victims in poor countries, or do they maintain that they’re a business and they’re here to make money? South Africa has the highest population of AIDS patients in the world. In the year 2000 roughly five million people (or 20%) of the population were infected with the disease. At this time some drugs to attack the virus had been developed. The problem was the cost of this treatment method (HAART) cost an estimated $10,000 to $15,000 a year. The average annual income in South Africa was approximately $2,000. What is a nation to do when a disease is spreading rapidly, killing off your people? The South African government decided to take matters into their own hands. If companies such as GSK wouldn’t make AIDS drugs affordable for their people they would get the drugs another way. In 1997 Nelson Mandela introduced the Medicines and Related Substances Control Amendment. With this amendment the South African government could import generic drugs. They saw this as the only way to get affordable AIDS drugs to help infected victims of the disease. In 1998 GSK and 41 other pharmaceutical companies filed a lawsuit against the South African government, brought on by the South African Medicines and Related Substances Control Amendment. The lawsuit argued that the amendment would allow the health minister to arbitrarily ignore patents on......

Words: 735 - Pages: 3

Premium Essay

Gsk Case Study

...CASE STUDY: GSK (GlaxoSmithKline) Warm-up: • Do you think that we should prevent pharmaceutical firms applying for patents? • Selling drugs online has become a common practice. Do you believe we should go further in this direction? • Is the wave of M&A beneficial for clients in the pharmaceutical industry? Question 1: Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. PESTEL analysis of the macro-environment surrounding the pharmaceutical industry: As a reminder: Macro-environment: PESTEL Industry (or sector): 5 forces of Porter + Life cycle THE PESTEL MODEL: 1. Political 2. Social 3. Environmental 4. Economic 5. Techonological 6. Legal SOCIAL FACTORS Ageing population: need more drugs Better informed customers: Firms should give more information, because when you’re sick the first thing you think of doing is looking up on the internet. Firms have to work on their communication Social responsibility: related to medications that are meant to cure people. How much money should be made from drugs that are saving lives? At which point should firms renounce to their huge benefits? Importance of emerging markets: some regions in Asia More: New industries for new diseases, geographical differences (some countries don’t have money to spend on drugs) ECONOMIC FACTORS Globalisation: market is going global concerning drugs and pharmaceutical......

Words: 925 - Pages: 4

Premium Essay

Gsk Case

...1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance, companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France, with less demand in new technologies. 2) The very selective anglo-saxon system which is looking for high technologies, excluding people who can pay for treatments. As we know the industry have to work on growing political focus on healthcare. Indeed, global governments are looking for healthcare savings especially in this time of economic crisis. Furthermore, as the European Union is trying to harmonize healthcare between its 27 members, pharmaceutical companies will have to introduce reference in pricing and to deal with increasing pressure on pricing. Economic: Due to the context of global economic crisis, the main threat for the industry stands in the reluctance of consumers to spend on healthcare. Like most of the sectors, pharmaceutical industry copes with a reduction in its growth, even if the market perspectives are positive. To emphasize: pharmaceutical growth is following the GDP growth. Social: As the over-65’s consume 4 time more than other citizens, the aged population represents an opportunity for the pharmaceutical companies which will have to respond to......

Words: 1150 - Pages: 5

Premium Essay

Corporate Social Responsibility

................................................................................................ 1 Core interest of GSK in Africa .................................................................................................... 1 Criticism of GSK ......................................................................................................................... 1 Access to Medicine (ATM) Outlook ............................................................................................ 2 Governance .................................................................................................................................... 2 Management Structures....................................................................................................... 3 Performance Management & Incentives ............................................................................. 3 Stakeholder Engagement..................................................................................................... 4 Innovation in General Access to Medicine Management .......................................................... 4 Pricing Policies adopted by GSK ................................................................................................. 5 Tiered (or equitable) Pricing Schemes ................................................................................ 6 Patents and Licensing...

Words: 3334 - Pages: 14

Premium Essay

Gsk Company Profile

...GlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK’s sales. The five largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both antidepression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin. Each of these drugs generated above £800 million of sales in 2003. GSK produces a broad range of products of special importance to developing countries, including: Anti-malaria drugs Zentel (albendazole), for de-worming and the prevention of lymphatic filariasis Pentosam, against leishmaniasis Anti-retrovirals (ARVs) for the treatment of HIV/AIDS Tuberculosis drugs Vaccines for developing......

Words: 18642 - Pages: 75

Free Essay

Management

...Ranitidine Hydrochloride prices have rebounded to Rs 700 in fag end of May 2008 Ranitidine HCl belongs to a class of medications, called H2–Blockers used for treatment of ulcers. Ranitidine HCl blocks the action of histamine (acid) on stomach cells thus reducing stomach acid production. Ranitidine HCl is useful in healing of stomach ulcers and reducing ulcer pain and has been effective in preventing ulcer recurrence when given in low doses for prolonged period of time. In doses higher than that used in ulcer treatment, Ranitidine HCl has been helpful in treating heartburn and in healing ulcer and inflammation of the throat resulting from the acid reflects. The product patent for Ranitidine HCl was held by GlaxoSmithkline (GSK) and was marketed under the brand name ‘Zantac’. The product patent for Ranitidine HCl held by GSK expired in 2002. Damand and Supply According to the industry sources, the annual requirement for Ranitidine HCl is around 6000MTPA. India, with around 3600MT of suppy, is the biggest supplier of Ranitidine to the world market. As the production os Ranitidine is very complex, the product is manufactured by few players only. These are; Neuland Laboratories, Shasun Chemicals and Drugs, SMS Pharmaceuticals, Orchev Pharma and Saraca Pharma. Producers in India SMS Pharmaceuticals: Hyderabad based SMS Pharmaceuticals is the largest producer of Ranitidine HCl and its intermediates in the world. The Company produces Ranitidine HCl in its Unit 1 located at......

Words: 1580 - Pages: 7

Premium Essay

Accounting Gsk

...(Exhibit 4) Some of the reasons for this growth are the increasingly elderly population and rising middle class within emerging markets. Since the global population is aging, there has also been demand for products designed for age-related conditions. Lastly, the emergence of new viruses, pandemics and drug-resistant infections has prompted more research and development (R&D) in the industry, increasing the number of products in the pipeline Concentration in this industry is low, as the large pharmaceutical manufacturers only account for 15% of the market share. The most important issue faced by large pharmaceutical companies globally is the expiration of their patents, which results in the production of generic drugs by other manufacturers at lower price. The last 4 years companies have faced a series of simultaneous patent expiries, leading to severe sales losses of up to $250 billion from 2012 until today. Lastly, global trade and regulations have an impact on pricing controls, which has led companies to alter their portfolios from primary-care blockbusters to specialties (IBIS). Pfizer Inc. (600 words) Pfizer, Inc. is the largest player in the global pharmaceutical industry, with an estimated market share of 4.2%. Pfizer is a research-based pharmaceutical company, which operates in 3 segments, Global Innovative Pharmaceutical (GIP), Global Established...

Words: 3225 - Pages: 13

Premium Essay

Ed; 3 ; Rc

...GlaxoSmithKline GlaxoSmithKline is a UK based pharmaceutical, biological and healthcare company. It is the world’s second largest pharmaceutical company. Glaxo Wellcome, which is formed from the merger of Glaxo Laboratories and Burroughs Wellcome & Company, together with the SmithKline Beecham and they have form the GlaxoSmithKline. In the year 2000, GlaxoSmithKline have the name and known as GSK. GSK had employs around 110,000 workers in 117 countries, and is including over 40,000 that participate in sales and marketing. There are few global headquarters which is separated in GSK House in Brebtfort, London, United Kingdom and United States. The London and New York stock exchanges have listed the GSK Company in their list. Some well known brands such as Ribena (beverage), Panadol Zantac (anti-ulcer), Zavirax (anti-viral), (pain relief) and Augmentin (antibiotic) which is selling by them. Mission statement: The GlaxoSmithKline (GSK) global quest is to improve the quality of human life by guiding people to do more, to let them feel better, and also live longer. Besides that, the GSK has to undertake the entrepreneurial spirit of enthusiasm. It is inspired by the constant search for the pursuit of innovation. GlaxoSmithKline attention to performance also made their complete realization and each and every citizen, as a global leader in world-class and unparalleled passion for the success of awareness contribute to the sense of urgency. In addition, two have been......

Words: 3608 - Pages: 15

Premium Essay

The Top Five Global Pharma Companies Where They

...sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis This report presents the cases of the top five global pharma companies: J&J, Pfizer, GSK, Novartis and SanofiAventis and identifies their key growth areas. Pooling data from 6 major investment institutions, it delivers a 360o analysis on these big five global pharma with further value add and refinement coming from 8 leading key opinion leaders, to produce an easy to read 25 page PowerPoint deck. Johnson & Johnson has reached a critical point in its product portfolio which should see the company convert from “cash cow” (high market share; low market growth) to “star” (high market share; high market growth) status by 2010. This is reflected in J&J having not less than 6 late stage drugs that will either unveil phase III data or be filed with the FDA within 2008 culminating in strong impact on its P&L account by 2010. Likewise the other cash cow Pfizer, boasts of at least 17 disclosed products under late phase development, with launches in the post-2010 period, thus are likely to buoy double digit sales growth beyond Lipitor patent expiry. GlaxoSmithKline on the other hand, has a product portfolio with a significant cash flow position this in turn has spurred on a meaningful gearing by GSK management. This puts the company firmly in a star performing position for 2008-2011. With asset consolidation of $23.5bn USD......

Words: 1107 - Pages: 5

Premium Essay

Macro Economic Factors

...we will highlight some of the activities of Glaxo-Smithkline (GSK) and how this company has evolved to adapt to the dynamic nature...

Words: 2748 - Pages: 11